最新刊期
卷 32 ， 期 6 ， 2022
- 摘要：Background and purpose: In clinical studies, checkpoint inhibitor-related pneumonitis (CIP) ranks first among the causes of death in programmed cell death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitor immune-related adverse events. Real-world CIP situations lack extensive population reports. This study aimed to understand the incidence of CIP in the real world of lung cancer in China, and to summarize its characteristics, treatment status and outcomes. Methods: This study retrospectively collected the essential clinical information of patients with an initral diagnosis of lung cancer who received treatment with immune checkpoint inhibitors (ICIs) at the First Affiliated Hospital of Guangzhou Medical University and Shanghai Pulmonary Hospital between January 2019 and September 2021. For patients with CIP, we also collected the time of its onset, grade, treatment regimen and outcome. The analyses of incidence, patient’s characteristics and the risk factors of CIP in overall and subgroup were carried out. Moreover, we analyzed the outcomes of patients treated with immunosuppressive therapy. Results: A total of 2 031 patients with immunotherapy were enrolled, with a CIP incidence rate of 7.2% (147/2 031), a severe CIP rate of 2.6% (52/2 031) and a mortality rate of 0.4% (9/2 031). The rate of severe grade in the population with CIP was 35.4%, and the mortality rate was 6.1% (9/147). Compared with non-CIP patients, more CIP patients were male, older (>65 years), with combination therapy, and on first- and second-line immunotherapy in advanced treatment. In subgroup analyses, the incidence of CIP was higher in men, the elderly (>65 years), squamous cancer, combination therapy, anti-PD-1 inhibitors, and first- and second-line therapy in advanced treatment. The median onset time of CIP in the real world was 148 days, with a double-peak characteristic, that was, 60-90 days and 150-210 days after immunotherapy were both the peak time periods for CIP onset. The incidence of CIP was also influenced by seasonality, with a high incidence in autumn and winter. All treated patients used corticosteroids as first-line treatment; the immunosuppressive treatment rate of CIP in this study was 76.2%. After treatment, 97.9% of mild CIP patients and 81.2% of severe CIP patients had a good prognosis, and 17.3% of severe CIP patients died due to CIP. Conclusion: In the real world, the incidence of CIP for lung cancer patients was 7.2%, incidence of severe CIP was 2.6%, and mortality rate was 0.4%; the incidence of severe disease in the population with CIP was 35.4%, and mortality rate was 6.1%. The median onset time of CIP was characterized by a double peak, and incidence of CIP was higher in autumn and winter. Men, the elderly, squamous cancer patients, patients on combination therapy, patients who used anti-PD-1 inhibitors, and patients with advanced treatment had higher incidence of CIP. Most patients with CIP had good outcomes after immunosuppressive therapy.关键词：Lung cancer;Checkpoint inhibitor-related pneumonitis;Immune-related adverse event;Immune checkpoint inhibitor;Epidemiology;Real-world research986|1887|0更新时间：2025-12-31
Specialists' Article
- 摘要：Lung cancer remains the malignant tumor with the highest morbidity and mortality in China, among which non-small cell lung cancer (NSCLC) accounts for more than 80%. Immune checkpoint inhibitors (ICIs)-based therapy targeting programmed death protein-1 (PD-1) or its ligand programmed death ligand-1 (PD-L1) has become one of the standard treatments for advanced NSCLC. This review, with the focus on advanced NSCLC, summarized the development of immunotherapy, discussed current problems, and challenges and proposed future directions.关键词：Non-small cell lung cancer;Immune checkpoint inhibitor;Immunotherapy3612|7479|0更新时间：2025-12-31
- 摘要：The PACIFIC trial uncovered a new era of immunotherapy in the multi-disciplinary treatment of unresectable locally advanced non-small cell lung cancer (LA-NSCLC), but also proposed a new question of how to further optimize radiotherapy and chemotherapy, in order to maximize synergistic effects with immunotherapy. The treatment progress of unresectable LA-NSCLC was reviewed in the context of immunotherapy. Updated data of the PACIFIC trial along with the research progress among special populations, especially for elderly patients, programmed death ligand-1 (PD-L1) expression negative and epidermal growth factor receptor (EGFR) gene mutant were summarized. Meanwhile, the optimal sequence of radiotherapy, chemotherapy and immunotherapy, the technical advancement and implementation of radiotherapy, including dose fractionation, target delineation and ray selection, were discussed, as well as its application prospect in the era of immunotherapy.关键词：Non-small cell lung cancer;Immunotherapy;Radiotherapy;Chemotherapy477|5402|0更新时间：2025-12-31
- 摘要：The corona virus disease 2019 (COVID-19) pandemic continues to severely impact healthcare systems around the world, and patients with cancer are even worse affected owing to compromised immune status and greater exposure risk. In the present review, we retrieved the relevant literature including guidelines and consensuses directly related to the purpose of this study from the PubMed database, and then summarized the research data on cancer and COVID-19, aiming to discuss the personal protection, systemic anti-cancer therapy, outcome of co-infection, and the clinical management strategy in this population. We found that patients with malignant tumors had a higher chance of suffering COVID-19, co-infection of whom had an even worse clinical prognosis, especially for those with lung cancer or hematologic cancers. Systemic chemotherapy may delay the clearance of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) virus of human body, and thus have a negative impact on the clinical outcomes of COVID-19, while certain endocrine therapy and targeted drugs having limited or no impact. There has been no sufficient evidence for the impact of immune checkpoint therapy on the outcomes of COVID-19 till now. It is of great value to strengthen the personal protection of patients, adjust the anti-tumor treatments rationally and optimize the clinical management processes.关键词：COVID-19;Malignant tumors;Chemotherapy;Anti-tumor therapy;Clinical outcome254|2619|0更新时间：2025-12-31
- 摘要：CD30, a member of tumor necrosis factor receptor family, is expressed in a variety of lymphoma subtypes, such as classic Hodgkin lymphoma (CHL) and anaplastic large cell lymphoma (ALCL). In addition to its diagnostic and prognostic values, CD30 has now been recognized as an effective target for antibody drug conjugate (ADC). With the progress of multiple clinical trials involving the anti-CD30-targeted therapy, a standardized detection and assessment of CD30 expression in lymphoma cases appear necessary. We thus reviewed in this article the CD30 expression patterns and the challenges on the CD30 detection and assessment in different lymphomas.关键词：Lymphoma;CD30;Biomarker;Targeted therapy151|4225|0更新时间：2025-12-31
Specialists' Commentary
- 摘要：Background and purpose: The Shanghai Municipal Center for Disease Control and Prevention provides annual updates on cancer occurrence and trends in Shanghai. This study aimed to investigate the cervical cancer incidence and mortality in 2016 and their trends from 2002 to 2016 in Shanghai. Methods: Data of new cervical cancer diagnoses and deaths from 2002 to 2016 were obtained from the population-based cancer registry and Vital Statistics System of Shanghai Municipal Center for Disease Control and Prevention. Cervical cancer incidence and mortality stratified by year of diagnosis or death, and age group were analyzed. Number, proportion, crude rate, age-specific rate, age-standardized rate and others were calculated. The number, proportion and rates of common cancers in different groups were also calculated. Trends in number, age-standardized rates and age-specific rates of incidence and death were estimated. Trends in age-standardized rates of incidence and death were estimated by Joinpoint analysis and characterized by the annual percent change (APC). The cases and proportion of selected diagnostic characteristics in different periods of diagnosis years grouped were also calculated. Segi’s 1960 world standard population was used for calculating age-standardized rates of incidence and mortality. Results: The new cervical cancer cases and deaths were 987 and 267 in Shanghai in 2016. The crude rate of incidence was 13.53/105, and the age-standardized rate of incidence was 8.26/105. The crude rate of mortality was 3.66/105, and the age-standardized rate of mortality was 1.87/105. The age-specific number and rate of incidence reached the peak in the age group of 55-59 years and 45-49 years respectively, while those of mortality reached the peak in the age group of 50-54 years and 80-84 years respectively. The standardized incidence rate of cervical cancer increased by an average annual growth of 12.51% from 2002 to 2010 and 3.12% per year from 2010 to 2016 in Shanghai. The standardized mortality rate increased by 4.52% per year from 2002 to 2016. The major histopathological type of cervical cancer was squamous cell carcinoma. The proportions of morphological verification and stage Ⅰwere increasing. Conclusions: In Shanghai, the incidence and mortality of cervical cancer were at a lower level of the world, but they were increasing. The current status and trends reflect Shanghai permanent population changes in risk factors, screening test use, diagnostic practices and treatment advances. Improvement of the surveillance and research on cervical cancer will help to promote more efficient control and prevention strategies and decrease cancer burden.关键词：Cervical cancer;Incidence;Mortality;Trends;Shanghai51|1569|0更新时间：2025-12-31
- 摘要：Background and purpose: Glioblastoma (GBM) is one of the most malignant brain tumors, however, the pathogenesis of GBM has not been thoroughly studied. The purpose of this study was to analyze the regulation of Yes-associated protein 1 (YAP1) by zinc finger DHHC domain-containing protein 12 (ZDHHC12), and the regulation of GBM tumor characteristics through the ZDHHC12/YAP1 axis. Methods: The expression of ZDHHC12 in normal brain tissue and GBM was analyzed in the The Cancer Genome Atlas (TCGA) database and Genotype-Tissue Expression (GTEx) database. Western blot and real-time fluorescence quantitative polymerase chain reaction (RTFQ-PCR) were used to detect the mRNA expression and protein levels in U87, U251 and NHA. ZDHHC12 was knocked down by designed siRNA in two GBM cell lines, U87 and U251, and the protein levels of YAP1 were detected. The interaction between endogenous and exogenous ZDHHC12 and YAP1 was verified by co-immunoprecipitation (Co-IP). The changes in proliferation and migration ability of GBM cells after knockdown of ZDHHC12 and restoration of YAP1 were analyzed by cell counting kit-8 (CCK-8) assay, cell plate clone formation assay and scratch assay. Changes in markers of epithelial-mesenchymal transition (EMT) in GBM cell lines after knockdown of ZDHHC12 and restoration of YAP1 were detected. The effect of ZDHHC12 on the prognosis of GBM patients was analyzed, and detection of the protein levels of ZDHHC12 and YAP1 in different tissue samples was carried out. Results: The analysis results of TCGA database and GTEx database showed that the expression of ZDHHC12 was significantly higher in GBM than in normal brain tissue (P<0.01), and the mRNA and protein levels of ZDHHC12 were higher in GBM cell lines than in NHAs cell lines. Knockdown of ZDHHC12 in both U87 and U251 GBM cell lines caused a decrease in YAP1 protein levels. Co-IP experiments verified the interaction between ZDHHC12 and YAP1 proteins. Knockdown of ZDHHC12 could significantly inhibit the proliferation and migration of GBM cells, and the difference was statistically significant (P<0.05). Knockdown of ZDHHC12 also caused changes in EMT-related markers. Restoration of YAP1 reversed the changes in GBM tumor properties induced by the knockdown of ZDHHC12. In the TCGA database, the expression of ZDHHC12 was also closely related to the prognosis of GBM patients. The expression of ZDHHC12 in tissues was positively correlated with YAP1 expression. Conclusion: ZDHHC12 is highly expressed in GBM and positively related to YAP1, and the ZDHHC12/YAP1 axis regulates GBM tumor characteristics.关键词：Glioblastoma;Zinc finger DHHC domain-containing protein 12;Yes-associated protein 1;Epithelial-mesenchymal transition37|3807|0更新时间：2025-12-31
- 摘要：Background and purpose: The role of neddylation modification in breast cancer has rarely been reported. Previous study found that neddylation modification blocking induced cellular senescence in breast cancer, however, the potential mechanism has not yet been fully elucidated. It is reported that lamin B1 deletion leads to cellular senescence. The purpose of this study was to investigate the correlation between neddylation modification and lamin B1 expression in breast cancer and its possible mechanism. Methods: Neural precursor cell expressed developmentally downregulated protein 8 (NEDD8) and NEDD8-activating enzyme 1 (NAE1), two key proteins of neddylation modification process, in addition to lamin B1 were immunohistochemically stained in tissue microarray from 113 breast cancer patients. The correlation of NEDD8 and NAE1 with lamin B1 was analyzed using Spearman’s rank analysis. The expression of NEDD8 was knocked down to block neddylation modification by CRISPR/Cas9 technique. Western blot assay was used to detect the regulation of lamin B1 by neddylation modification and its mechanisms. Results: Lamin B1 expression was positively correlated with NEDD8 (r=0.817, P<0.000 1) and NAE1 (r=0.406, P<0.000 1) expressions. Blocking neddylation modification by knocking down NEDD8 significantly inhibited the expression of lamin B1. Silencing of p53 partially reversed the inhibition of lamin B1 by neddylation modification blocking. Conclusion: Neddylation modification was positively correlated with lamin B1 expression. Targeting neddylation modification inhibited the expression of lamin B1 in a p53-dependent manner. This study provides new target and clue for the treatment of breast cancer.关键词：Ubiquitin-like;Neddylation;Lamin B1;Breast cancer15|1269|0更新时间：2025-12-31
Article
- 关键词：Esophagectomy;Esophageal squamous cell carcinoma;Esophagotracheal fistula23|1052|0更新时间：2025-12-31
个案报道
- 摘要：Neuroendocrine neoplasm (NEN) is a kind of rare tumor that originated from peptidergic neurons and neuroendocrine cells, which has neuroendocrine differentiation and expresses neuroendocrine markers. NEN occurs in all parts of the body, especially in lung, stomach, intestine and pancreas. Domestic and international research data suggested that the incidences of NEN were rising. The results of epidemiological investigation showed that compared with other types of tumors, the incidences of NEN increased more significantly. On the basis of existing evidence, combined with domestic and international guidelines and consensus, the Society of Neuroendocrine Neoplasm of China Anti-Cancer Association has formulated its first guideline for diagnosis and treatment of NEN as reference for clinical physicians.关键词：Neuroendocrine neoplasm;Diagnosis;Treatment;Guideline2846|4443|0更新时间：2025-12-31
Guideline and Consensus
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
0